Brief: Tango Therapeutics Announces Combination Of Vopimetostat And Daraxonrasib Demonstrated 92% Objective Response Rate In Pancreatic Cancer
08/06/2026 12:01
BRIEF-Tango Therapeutics Announces Combination Of Vopimetostat And Daraxonrasib Demonstrated 92% Objective Response Rate In Pancreatic Cancer June 8 (Reuters) - Tango Therapeutics Inc TNGX.O:
TANGO THERAPEUTICS ANNOUNCES COMBINATION OF VOPIMETOSTAT AND DARAXONRASIB DEMONSTRATED 92% OBJECTIVE RESPONSE RATE IN PANCREATIC CANCER
TANGO THERAPEUTICS - VOPIMETOSTAT PLUS DARAXONRASIB GENERALLY WELL TOLERATED WITH NO NEW SAFETY SIGNALS
TANGO THERAPEUTICS - TO ADVANCE VOPIMETOSTAT PLUS DARAXONRASIB INTO PHASE 3 FOR MTAP-DELETED PANCREATIC CANCER
Source text: ID:nGNX5gwqWz
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,